Last reviewed · How we verify
NCT04027127: ACS-NETRİN-1
The Role of Netrin -1 in Acute Coronary Syndrome
NA trial testing netrin-1 value on admission to hospital in Acute Coronary Syndrome in 238 participants. Completed in 15 June 2018.
15 August 2014
Quick facts
| Lead sponsor | Aksaray University Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 238 |
| Start date | 15 September 2013 |
| Primary completion | 15 August 2014 |
| Estimated completion | 15 June 2018 |
Drugs / interventions tested
- netrin-1 value on admission to hospital
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Sponsor
Aksaray University Training and Research Hospital
Who can join
18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury.
Ruan W, Ma X, Bang IH, Liang Y, et al · · 2022 · cited 24× · PMID 36009485 · DOI 10.3390/biomedicines10081939
Verify or expand the search:
- PubMed search for NCT04027127
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Aksaray University Training and Research Hospital trials
Trials by the same sponsor.
- NCT07379879 — Acute Neurochemical and Cognitive Changes After HIIT vs MICT/LICT · NA · completed
- NCT07191015 — Temporal Dynamics of Irisin · NA · completed
- NCT07395765 — Comparing Touch-Limited and Free-Play 4v4 Small-Sided Games (SSGs) · NA · completed
- NCT07137611 — Effects of Different Types of Exercise on BDNF and Cognitive Performance (Exercise-BDNF) · NA · completed
- NCT07146490 — Effects of Different Types of Exercise on Irisin and Cognitive Performance (Exercise-Irisin) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04027127 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aksaray University Training and Research Hospital
- Last refreshed: 19 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04027127.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing